Panagora Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.9M | Buy |
546,517
+297,110
| +119% | +$6.18M | 0.04% | 325 |
|
|
2026
Q1 | $5.83M | Buy |
249,407
+124,308
| +99% | +$2.7M | 0.02% | 388 |
|
|
2025
Q4 | $2.63M | Sell |
125,099
-30,217
| -19% | -$527K | 0.01% | 505 |
|
|
2025
Q3 | $2.39M | Buy |
+155,316
| New | +$2.03M | 0.01% | 484 |
|
|
2024
Q3 | – | Sell |
-82,849
| Closed | -$1.7M | – | 1257 |
|
|
2024
Q2 | $1.7M | Sell |
82,849
-154,157
| -65% | -$3.23M | 0.01% | 563 |
|
|
2024
Q1 | $5.64M | Buy |
237,006
+62,862
| +36% | +$1.4M | 0.03% | 319 |
|
|
2023
Q4 | $3.76M | Buy |
174,144
+82,645
| +90% | +$1.27M | 0.02% | 386 |
|
|
2023
Q3 | $1.33M | Sell |
91,499
-175,583
| -66% | -$3.32M | 0.01% | 684 |
|
|
2023
Q2 | $5.59M | Buy |
267,082
+84,701
| +46% | +$1.76M | 0.03% | 308 |
|
|
2023
Q1 | $3.85M | Buy |
182,381
+3,296
| +2% | +$82K | 0.02% | 423 |
|
|
2022
Q4 | $4.56M | Buy |
179,085
+110,282
| +160% | +$2.57M | 0.03% | 407 |
|
|
2022
Q3 | $1.65M | Sell |
68,803
-138,015
| -67% | -$3.1M | 0.01% | 670 |
|
|
2022
Q2 | $3.98M | Sell |
206,818
-3,017
| -1% | -$50.3K | 0.03% | 441 |
|
|
2022
Q1 | $3.65M | Buy |
209,835
+8,993
| +4% | +$151K | 0.02% | 495 |
|
|
2021
Q4 | $4.4M | Sell |
200,842
-3,339
| -2% | -$61.7K | 0.02% | 435 |
|
|
2021
Q3 | $3.9M | Sell |
204,181
-1,820
| -0.9% | -$30.3K | 0.02% | 489 |
|
|
2021
Q2 | $3.54M | Buy |
206,001
+83,361
| +68% | +$1.53M | 0.02% | 528 |
|
|
2021
Q1 | $2.74M | Buy |
122,640
+12,331
| +11% | +$279K | 0.02% | 630 |
|
|
2020
Q4 | $2.45M | Buy |
110,309
+55,020
| +100% | +$1.14M | 0.01% | 628 |
|
|
2020
Q3 | $816K | Sell |
55,289
-14,186
| -20% | -$216K | 0.01% | 972 |
|
|
2020
Q2 | $1.03M | Hold |
69,475
| – | – | 0.01% | 922 |
|
|
2020
Q1 | $761K | Sell |
69,475
-62,004
| -47% | -$582K | 0.01% | 947 |
|
|
2019
Q4 | $1.15M | Sell |
131,479
-78,677
| -37% | -$578K | 0.01% | 1002 |
|
|
2019
Q3 | $1.57M | Buy |
210,156
+11,986
| +6% | +$109K | 0.01% | 843 |
|
|
2019
Q2 | $1.84M | Buy |
198,170
+50,030
| +34% | +$365K | 0.01% | 870 |
|
|
2019
Q1 | $778K | Sell |
148,140
-12,155
| -8% | -$69.3K | ﹤0.01% | 1230 |
|
|
2018
Q4 | $713K | Buy |
160,295
+3,782
| +2% | +$20.7K | ﹤0.01% | 1210 |
|
|
2018
Q3 | $1.26M | Buy |
156,513
+69,130
| +79% | +$493K | ﹤0.01% | 1029 |
|
|
2018
Q2 | $613K | Buy |
87,383
+31,125
| +55% | +$305K | ﹤0.01% | 1337 |
|
|
2018
Q1 | $801K | Sell |
56,258
-24,798
| -31% | -$263K | ﹤0.01% | 1238 |
|
|
2017
Q4 | $710K | Buy |
+81,056
| New | +$802K | ﹤0.01% | 1259 |
|
Other funds holding SNDX
KCM
DM
EP
HRCM
Panagora Asset Management's SNDX Position: Q2 2026 in Review
Panagora Asset Management increased its Syndax Pharmaceuticals (SNDX) stake by 119% in Q2 2026, buying an estimated $6.18M and bringing the position to 546,517 shares worth $11.9M. The position accounts for 0.04% of the portfolio, ranked #325.
Panagora Asset Management first reported a position in SNDX in Q4 2017 and has held it in 31 quarters since. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.
- Panagora Asset Management held 546,517 shares of Syndax Pharmaceuticals worth $11.9M as of Q2 2026.
- Panagora Asset Management bought 297,110 Syndax Pharmaceuticals shares in Q2 2026, an estimated $6.18M.
- Syndax Pharmaceuticals made up 0.04% of Panagora Asset Management's portfolio in Q2 2026, its #325 holding.
- Panagora Asset Management first reported a position in Syndax Pharmaceuticals in Q4 2017 and has held it in 31 quarters since.
- 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.
Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.